key: cord-0906670-jmrrl2kl
authors: Li, Jian; Lin, Cheng; Zhou, Xuelan; Zhong, Fanglin; Zeng, Pei; Yang, Yang; Zhang, Yuting; Yu, Bo; Fan, Xiaona; McCormick, Peter J.; Fu, Rui; Fu, Yang; Jiang, Haihai; Zhang, Jin
title: Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332
date: 2022-04-07
journal: J Virol
DOI: 10.1128/jvi.02013-21
sha: fab89802ea2cde5c94e06003c4d7e7826d2550ef
doc_id: 906670
cord_uid: jmrrl2kl

The high mutation rate of COVID-19 and the prevalence of multiple variants strongly support the need for pharmacological options to complement vaccine strategies. One region that appears highly conserved among different genera of coronaviruses is the substrate-binding site of the main protease (M(pro) or 3CL(pro)), making it an attractive target for the development of broad-spectrum drugs for multiple coronaviruses. PF-07321332, developed by Pfizer, is the first orally administered inhibitor targeting the main protease of SARS-CoV-2, which also has shown potency against other coronaviruses. Here, we report three crystal structures of the main protease of SARS-CoV-2, SARS-CoV, and Middle East respiratory syndrome (MERS)-CoV bound to the inhibitor PF-07321332. The structures reveal a ligand-binding site that is conserved among SARS-CoV-2, SARS-CoV, and MERS-CoV, providing insights into the mechanism of inhibition of viral replication. The long and narrow cavity in the cleft between domains I and II of the main protease harbors multiple inhibitor-binding sites, where PF-07321332 occupies subsites S1, S2, and S4 and appears more restricted than other inhibitors. A detailed analysis of these structures illuminated key structural determinants essential for inhibition and elucidated the binding mode of action of the main proteases from different coronaviruses. Given the importance of the main protease for the treatment of SARS-CoV-2 infection, insights derived from this study should accelerate the design of safer and more effective antivirals. IMPORTANCE The current pandemic of multiple variants has created an urgent need for effective inhibitors of SARS-CoV-2 to complement vaccine strategies. PF-07321332, developed by Pfizer, is the first orally administered coronavirus-specific main protease inhibitor approved by the FDA. We solved the crystal structures of the main protease of SARS-CoV-2, SARS-CoV, and MERS-CoV that bound to the PF-07321332, suggesting PF-07321332 is a broad-spectrum inhibitor for coronaviruses. Structures of the main protease inhibitor complexes present an opportunity to discover safer and more effective inhibitors for COVID-19.

world (1, 2) . There have been several coronaviruses in human history that are pathogenic to humans, among which two were associated with severe respiratory disease outbreaks, SARS-CoV (severe acute respiratory syndrome coronavirus first emerged in Guangdong China in 2002) and MERS-CoV (Middle East respiratory syndrome coronavirus first detected in Saudi Arabia in 2012) (3) (4) (5) . Genomic sequencing data showed that SARS-CoV-2 shares 79.6% sequence identity with SARS-CoV (1, (6) (7) (8) . As SARS-CoV and SARS-CoV-2 successively emerged and COVID-19 continues spreading throughout the globe, developing broad-spectrum drugs remains an urgent and unmet clinical need in the treatment and prevention of COVID-19 infections.

Viral enzymes and proteins of CoVs that are involved in coronavirus replication are potential drug targets for COVID- 19 . In particular, the main protease (M pro or 3CL pro ), which cleaves the replicase polyproteins at 11 sites, is one of the most attractive targets for numerous classes of small molecule inhibitors for the development of drugs against coronavirus infections (9, 10) . M pro is highly conserved among coronaviruses, and the substrate-binding site in M pro also shares several common features (6) . Because M pro has no human homolog, M pro inhibitors should be highly specific to SARS-CoV-2 and have minimal side effects (11) . Unfortunately, although several peptidomimetic covalent inhibitors of M pro have been reported, few candidates have progressed into clinical trials (6, (12) (13) (14) .

We previously screened an in-house small molecule library and identified shikonin as a noncovalent inhibitor for SARS-CoV-2 and SARS-CoV M pro in vitro, with a half-maximum inhibitory concentration (IC 50 ) of 1.57 mM and 7.89 mM, respectively (15, 16) . In addition, crystal structures of SARS-CoV-2 M pro with the antineoplastic drug carmofur and the natural products baicailin and baicalein have also been solved recently (17, 18) . Despite the progress made in understanding the origin of human coronaviruses as well as the prediction and prevention of the emerging pandemics, we still lack effective and safe drugs and therapies to combat the global pandemic caused by coronavirus (5, 19, 20) .

In 2021, Pfizer initiated a phase 1 clinical trial (NCT04756531) and later the phase 2/ 3 clinical trials (NCT04960202, NCT05011513) of a novel antiviral therapeutic agent against SARS-CoV-2. The clinical candidate, PF-07321332, is the first orally administered coronavirus-specific protease inhibitor, which has shown potent antiviral activity against SARS-CoV-2 in vitro, as well as activity against other coronaviruses (21) . As a protease inhibitor, PF-07321332 binds to the viral enzyme and can block the activity of the protease that the coronavirus needs to reproduce itself. Ritonavir, an inhibitor of a key liver enzyme called CYP3A, can boost and maintain the plasma concentration of PF-07321332 when coadministered. This kind of strategy has been used to effectively treat other viral pathogens, such as HIV and hepatitis C virus. Recently, the emergency use of Paxlovid (PF-07321332 and ritonavir) has been authorized by the U.S. Food and Drug Administration (FDA). Thus, PF-07321332 could be an encouraging antiviral with potential for use in the treatment of COVID-19, as well as potential use to address future coronavirus threats.

In this study, we aim to explore the molecular basis for the small molecule inhibitor PF-07321332 targeting M pro of coronaviruses. We found that PF-07321332 potently inhibits the enzymatic activity of SARS-CoV-2 M pro . We then determined the crystal structures of complexes of the main protease of SARS-CoV-2, SARS-CoV, and MERS-CoV bound to the inhibitor PF-07321332, revealing a novel binding mode of M pro . Structural comparison with reported M pro -inhibitor complex structures provides insight into the mechanism of M pro inhibition by a small molecule inhibitor and a framework for small molecule drug discovery.

Inhibitory activity of PF-07321332 against SARS-CoV-2 M pro . We purified the M pro of SARS-CoV-2 as previously reported (15) . A fluorescence resonance energy transfer (FRET) assay was employed to determine the inhibitory activity of PF-07321332 against SARS-CoV-2 M pro . Ebselen was used as a control with an IC 50 value of 0.365 mM, which is similar to that determined in previous studies (12, 22) . The results showed that PF-07321332 has a potent inhibition, with the IC 50 value against the M pro of SARS-CoV-2 being 0.023 mM (Fig. 1 ), which is much lower than that of recently reported covalent inhibitors such as boceprevir, leupeptin, and carmofur (17, 23, 24) .

Inhibitory mechanisms of PF-07321332 against SARS-CoV-2 M pro . In order to figure out the inhibitory mechanisms of PF-07321332, we determined the crystal structure of SARS-CoV-2 M pro in complex with PF-07321332 (PFM pro -Co) at 1.5-Å resolution using the cocrystallization method (see Fig. S1 in the supplemental material, Table 1 ). By comparison with the apo structure of SARS-CoV-2 M pro at pH 7.5, the root mean square deviation (RMSD) of equivalent Ca positions between apo Mpro and PFM pro -Co is ;0.985 Å (Fig. S2 ). As shown in Fig. 2 , the M pro molecule in the complex structure forms a homodimer and contains three domains, namely, domain I (residues 10 to 99), domain II (residues 100 to 184), and domain III (residues 201 to 303). PF-07321332 can be found in both protomer A and protomer B ( Fig. 2A) . Specifically, PF-07321332 binds to the active site situated in the cleft between domains I and II of M pro in an extended conformation and occupies subsites S1, S2, and S4 of SARS-CoV-2 M pro (Fig. 2B ). The electron density map unambiguously shows that nitrile carbon of PF-07321332 forms a C-S covalent bond with the sulfur atom of catalytic residue C145 (Fig. 2C ). The imine nitrogen of the thioimidate moiety occupies the oxyanion hole and forms hydrogen bonds with the backbone NH of C145 and the oxygen from a water molecule for stabilization. Besides the typical covalent interaction, PF-07321332 forms multiple noncovalent interactions with the active site. According to the Berger and Schechter nomenclature, PF-07321332 consists of five moieties, namely, P1 to P4 and P19. As shown in Fig. 2D and E, PF-07321332 contains a g-lactam ring at the P1 position just before the warhead nitrile group. The lactam ring inserts into the S1 subsite, with the oxygen and nitrogen atoms of the lactam ring forming hydrogen bonds with the N« 2 of H163 and carboxy group of Structure of M pro of CoVs Bound to Drug PF-07321332 Journal of Virology E166, respectively. Further, a hydrogen bond is also found between the amide nitrogen at the P1 moiety and the main-chain carbonyl oxygen of H164. The P2 position contains a dimethyl cyclopropyl proline (DMCP) moiety which inserts into the S2 subsite and mainly forms hydrophobic interactions, similar to the previously reported compound boceprevir (24) . PF-07321332 presents a tert-leucine residue at the P3 position. However, limited interactions are observed between the P3 moiety of PF-07321332 and the S3 subsite of M pro . PF-07321332 displays a trifluoromethyl group at the P4 position. The amide nitrogen at the P4 position forms a hydrogen bond with the main chain carbonyl oxygen of E166, while the trifluoromethyl group forms additional hydrogen bonds by interacting with the nitrogen atom of Q192 and a water molecule. Thus, PF-07321332 occupies the active site of SARS-CoV M pro by covalently binding to C145 and noncovalently interacting with conserved residues, including Cy145, H163, H164, E166, and Q192. The crystal structure of the M pro -PF-07321332 complex (PFM pro -So) has also been solved at 1.9-Å resolution by soaking (Table 1 ). By superimposition of PFM pro -Co and PFM pro -So, we found that the binding mode of PF-07321332 with SARS-CoV-2 Mpro was highly similar to the RMSD, being 0.781 Å over the 523 best-aligned Ca atoms (Fig. S3) .

Crystal structures of PF-07321332 in complex with SARS-CoV and MERS-CoV M pro . We also determined the crystal structure of PF-07321332 in complex with SARS-CoV and MERS-CoV M pro at 2.0-Å and 2.5-Å resolutions (Fig. S1, Table 1 ), respectively. PF-07321332 displays a highly similar conformation in the substrate-binding site of SARS-CoV, MERS-CoV, and SARS-CoV-2 M pro , even though the orientation of each moiety of PF-07321332 has slight differences ( Fig. 3A and B) . Like the case with SARS-CoV-2 M pro , PF-07321332 fits into the S1, S2, and S4 subsites and forms a covalent bond with the catalytic residue cysteine as expected ( Fig. 3C and D) . In addition, several amino acid residues, including F140, C145, H163, H164, E166, and Q192, in the protease form hydrogen bond interactions with the inhibitor in the SARS-CoV M pro -PF-07321332 complex. The key residues of MERS-CoV M pro interacting with PF-07321332 are highly conserved (Fig. 3E to H) . These observations are consistent with the fact that the structure of M pro in the coronaviruses is highly conserved and that PF-07321332 may be a potent inhibitor with broad-spectrum potential to defeat diseases caused by various coronaviruses.

Structural comparison of PF-07321332 with other covalent inhibitors in complex with SARS-CoV-2 M pro . Several covalent inhibitors that show good inhibitory activity of the SARS-CoV-2 main protease have recently been reported (Table S1 ). Among these, the structures of 13b and N3 complexed with M pro have been determined (12, 14) . Based on the complex structure, the covalent inhibitor 11a was designed with better inhibitory activities (6) . The clinically approved drugs carmofur and boceprevir were repurposed, and they displayed low micromolar inhibitory activity against SARS-CoV-2 M pro (17, 24) , while the other three preclinical inhibitors, GC376 (24), 5h (25) , and MPI3 (26), showed inhibitory activities (K i or IC 50 ) in the nanomolar range. We compared the structures of these recently identified covalent inhibitors complexed with SARS-CoV-2 M pro . All these small molecules form a C-S covalent bond with the catalytic residue cysteine (Fig. 4) and display a lactam ring at the P1 position which fits well with the S1 subsite except for carmofur and boceprevir. The amide nitrogen of the lactam ring can form hydrogen-bond interactions with the ketonic oxygen of Glu166 or Phe140, while the oxygen atom forms hydrogen-bond interactions with the backbone NH of Glu166 or N« 2 of His163. Subsite S2 of SARS-CoV-2 M pro appears to prefer hydrophobic interactions, and all these inhibitors display a hydrophobic group at the P2 position, such as isopropyl and the dimethyl cyclopropyl proline (DMCP) group. However, the P3 position of these inhibitors does not fit well with the S3 pocket. Indeed, structural optimization may be conducted in the future to investigate more suitable groups for this subsite. The binding pattern of PF-07321332 is similar to that of boceprevir at the P4 position but differs at substitution of F atoms and formation of hydrogen bonds with Q192. Therefore, structures of inhibitors in complex with M pro reported in this study and other studies, will provide the structural basis for the development and optimization of more potent drugs against SARS-CoV-2 infection. 

There is an urgent need to develop effective drugs as the novel coronavirus pandemic continues to wreak havoc on human society. M pro is a promising drug target for its vital role in viral replication and high conservation among all coronaviruses and because it has no homolog in humans. Although a great number of inhibitors have shown inhibitory activity against M pro , most of these are not potent enough and not highly bioavailable following oral administration, which limits its clinical application to hospitalized patients with relatively advanced disease. Thus, potent orally bioavailable antiviral drugs for treatment of SARS-CoV-2 infection are urgently needed. PF-07321332 is the first orally available antiviral drug developed by Pfizer to tackle the SARS-CoV-2 virus by targeting its M pro (21, 27) . In this study, we found that PF-07321332 is a potent inhibitor with an IC 50 of 0.023 mM. As shown in Table S1 , this value is a little higher than that of MPI3 (IC 50 , 8.5 nM) but lower than that of most reported inhibitors, including 11a (IC 50 , 0.053 mM) (6), 13b (IC 50 , 0.67 mM) (14) , boceprevir (IC 50 , 8.0 mM) (24) , and GC376 (IC 50 , 0.15 mM) (24) , which suggests its huge potential to treat COVID-19 clinically. In addition, the main advantage of PF-07321332 with respect to other inhibitors of SARS-CoV-2 M pro is the possibility of oral administration, a feature that could dramatically facilitate the treatment of COVID-19.

We also solved the crystal structure of PF-07321332 in complex with M pro of three deadly coronoviruses (SARS-CoV-2, SARS-CoV, and MERS-CoV), which is of great importance for structure-based drug development. The complex structures indicate that PF-07321332 covalently bound to the catalytic cysteine of M pro and formed multiple hydrogen bonds with conserved residues within the active site. best-aligned C a atoms, respectively. Compared with other covalent inhibitors, PF-07321332 employs a unique binding pattern to SARS-CoV-2 M pro . Further structure-based optimization of such covalent inhibitors will help generate drugs against the current COVID-19 pandemic with high efficiency and a broad spectrum.

Another orally bioavailable drug candidate, masitinib, has been demonstrated to show an inhibitory effect against SAR-CoV-2 M pro . Until now, masitinib has been approved for treatment of mast cell tumors in dogs and evaluated in phase 2 and 3 clinical trials in humans for the treatment of cancer, asthma, Alzheimer's disease, multiple sclerosis, and amyotrophic lateral sclerosis (29) . However, unlike PF-07321332 as a covalent inhibitor, masitinib is a noncovalent inhibitor, which could complement the design of covalent inhibitors against the SARS-CoV-2 main protease. Both covalent and noncovalent M pro inhibitor will contribute to increased public health preparedness for potential future pandemics.

Expression and purification of human CoVs. The codon-optimized cDNAs for M pro of SARS-CoV-2, SARS-CoV, and MERS-CoV were synthesized fused with 6Â His at the N terminus. Synthesized genes were subcloned into the pET-28a vector. The expression and purification of each main protease were performed by a standard method described previously by our lab (15) .

Enzymatic assays. PF-07321332 was purchased from MedChemExpress (MCE; Chemical Abstracts Service [CAS] no. 2628280-40-8). Fluorogenic substrates as a donor and quencher pair were synthesized. The IC 50 values of PF-07321332 against the SARS-CoV-2 main protease were measured with a common protocol as the following: first, 1 mL of main protease (200 nM) was incubated with various concentrations of testing inhibitors at room temperature for 30 min in its reaction buffer (50 mM Tris 7.3,150 mM NaCl, 1 mM EDTA) in a 384-well plate, and then fluorescence resonance energy transfer (FRET) substrate was added to the reaction system. The reaction was monitored for 20 min, and the data were calculated at 10 min intervals by linear regression. Ebselen was used as a positive control. The IC 50 was determined by plotting the initial velocity against various concentrations of testing inhibitor by using the doseresponse curve in GraphPad Prism software.

Crystallization. Cocrystallization of SARS-CoV-2 M pro with PF-07321332 (0.1 M HEPES, pH 7.5, 20% wt/vol PEG 10,000), SARS-CoV M pro with PF-07321332 (0.1 M HEPES, pH 7.5, 10% PEG 8,000, 8% ethylene glycol), and MERS-CoV M pro with PF-07321332 (10% PEG 200, 0.1 M bis-Tris-propane, pH 9.0, 18% PEG 8,000) was carried out at 20°C using the hanging drop vapor-diffusion method. PF-07321332 was added to M pro s according to a 3:1 molar ratio, and the mixture was incubated for 30 min on ice. After 3 to 5 days, the complex crystals of M pro s with PF-07321332 were obtained. For the soaking method, SARS-CoV-2 M pro crystals were obtained first using the sitting-drop vapor diffusion method at 20°C. PF-07321332 was then soaked with crystals of SARS-CoV-2 M pro (0.1 M HEPES sodium, pH 7.5, 10% vol/vol 2-propanol, 20% wt/vol PEG 4,000) within 24 h.

Data collection, structure determination, and refinement. The crystals were tailored with cryoloop and then flash-frozen in liquid nitrogen to collect better X-ray data. All data sets were collected at 100 K on a macromolecular crystallography beamline 17U1 (BL17U1) at the Shanghai Synchrotron Radiation Facility (SSRF, Shanghai, China). All collected data were handled with the HKL 2000 software Structure of M pro of CoVs Bound to Drug PF-07321332

Journal of Virology package. The structures were determined by molecular replacement with Phenix software. The program Coot was used to rebuild the initial model. The complete data collection and statistics of refinement are shown in Table 1 . Data availability. Coordinates and structure factors for the SARS-CoV M pro -PF-07321332, SARS-CoV-2 M pro -PF-07321332 (soaking and cocrystallization), and MERS-CoV M pro -PF-07321332 complexes have been deposited in the Protein Data Bank (PDB) under accession numbers 7VLO, 7VLP, 7VLQ, and 7VTC, respectively.

Supplemental material is available online only. SUPPLEMENTAL FILE 1, PDF file, 0.5 MB.

We thank the cryo-electron microscopy (cryo-EM) center of the Southern University of Science and Technology for our cryo-EM work and for their help with cryo-EM data collection.

J J.L. and J.Z. initiated and supervised the project. C.L., X.Z., F.Z., and P.Z. crystallized the protein complexes and performed the soaking experiments. J.L., C.L., X.Z., F.Z., P.Z., and J.Z. collected X-ray data and solved and refined structures. B.Y., Y.Z., and H.J. performed docking and identified compounds to be tested in the initial screens and assisted with the enzymatic assay by FRET assay. H.J., P.J.M., Y.Y., X.F., Y.F., and R.F. assisted with the design of experiments, project management, and interpretation of results.

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

WHO. WHO COVID-19 dashboard

Feng Z. 2020. Early transmission dynamics in

China Novel Coronavirus Investigating and Research Team. 2020. A novel coronavirus from patients with pneumonia in China

Evidence supporting a zoonotic origin of human coronavirus strain NL63

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A new coronavirus associated with human respiratory disease in China

Coronaviruses: drug discovery and therapeutic options

Coronavirus main proteinase (3CL pro ) structure: basis for design of anti-SARS drugs

The newly emerged SARS-like coronavirus HCoV-EMC also has an "Achilles' heel": current effective inhibitor targeting a 3C-like protease

Structure of M pro of CoVs Bound to Drug PF-07321332 Journal of Virology

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

2020. a-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors

Crystal structure of SARS-CoV-2 main protease in complex with the natural product inhibitor shikonin illuminates a unique binding mode

Structure-based discovery and structural basis of a novel broad-spectrum natural product against the main protease of coronavirus

Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur

Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients

Bat origin of human coronaviruses

Further evidence for bats as the evolutionary source of Middle East respiratory syndrome coronavirus

An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19

Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives

Mechanism of microbial metabolite leupeptin in the treatment of COVID-19 by traditional Chinese medicine herbs

Both boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease

A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication

A quick route to multiple highly potent SARS-CoV-2 main protease inhibitors

Computational simulations on the binding and reactivity of a nitrile inhibitor of the SARS-CoV-2 main protease

Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332

Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2